Hotgen(SH:688068) 智通财经网·2025-10-22 08:16Core Viewpoint - The announcement from Hotgen Biotech (688068.SH) indicates that its affiliate, Beijing ShunJing Biopharmaceutical Technology Co., Ltd., has reported positive preliminary results from the Phase Ib clinical trial of its innovative drug SGC001 injection for treating ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI) [1] Group 1 - The preliminary efficacy results show that SGC001 at doses of 600mg and 900mg demonstrated a significant trend in myocardial protection compared to the placebo group, evidenced by a reduction in myocardial infarction area percentage (IS%) [1] - The median reduction in myocardial infarction area percentage for the mid-high dose groups was 20.5% and 38.1%, respectively, indicating a dose-dependent increase in efficacy [1] - The time required for high-sensitivity troponin I (hsTnI) and high-sensitivity C-reactive protein (hs-CRP) to return to normal levels was shorter in the treatment groups compared to the placebo group [1] Group 2 - The project will continue to follow the clinical trial protocol for further clinical work [1]